Pericarditis Drugs Market

Pericarditis is the inflammation of the pericardium. Pericardium is two thin layers of a sac like structure of tissues that surrounds the heart. The pericardium holds the heart in place and helps it work. It is a small amount of fluid that keeps both the layers separated from each other so that there is no friction between the layers. Pericarditis often causes chest pain and other symptoms too. The harsh chest pain associated with pericardium occurs when the layers of the pericardium rub against each other. Pericarditis usually begins suddenly but does not last for long.When symptoms related to pericarditis develops more gradually or persists, it is considered as chronic pericarditis. Most cases of pericarditis are mild and usually improve on their own. The common symptoms related to pericarditis include cough; leg or abdominal swelling; low-grade fever; heart palpitations; shortness of breath when reclining; an overall sense of weakness, feeling sick or fatigue; and sharp, piercing chest pain. Pericarditis can be diagnosed with the help of electrocardiogram results, echocardiogram, physical examination, cardiac MRI, and reported symptoms.

Pericarditis Drugs Market contains market size and forecasts of Pericarditis Drugs in Global, including the following market information:

Global Pericarditis Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Pericarditis Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

By Drug Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Pericarditis Drugs include Pfizer Inc, Sanofi, Novartis, Bayer, AstraZeneca, Takeda Pharmaceuticals Industries Ltd, Teva Pharmaceutical Industries Ltd, Merck & Co., Inc and Abbive(Allergan), etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Pericarditis Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Pericarditis Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Pericarditis Drugs Market Segment Percentages, by Type, 2021 (%)

By Drug

Nonsteroidal Anti-Inflammatory Agents (NSAIDs)

Colchicine

Steroids

Antibiotics

Others

By Route of Administration

Intravenous

Oral

Others

By Disease

Acute Pericarditis

Chronic Pericarditis

Recurrent Pericarditis

Idiopathic Pericarditis

Global Pericarditis Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Pericarditis Drugs Market Segment Percentages, by Application, 2021 (%)

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Global Pericarditis Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Pericarditis Drugs Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Pericarditis Drugs revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Pericarditis Drugs revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Pfizer Inc

Sanofi

Novartis

Bayer

AstraZeneca

Takeda Pharmaceuticals Industries Ltd

Teva Pharmaceutical Industries Ltd

Merck & Co., Inc

Abbive(Allergan)

Hikma Pharmaceuticals PLC

Avion Pharmaceuticals LLC

Dr. Reddy?s Laboratories Ltd

Viatris

Amneal Pharmaceuticals LLC

Sun Pharmaceuticals Industries Ltd

Lupin